Bradanicline
Bradanicline is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target neuronal acetylcholine receptor subunit alpha-7.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 2 | — | — | — | 2 |
| Cognitive dysfunction | D060825 | G31.84 | — | 2 | — | — | — | 2 | |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BRADANICLINE |
| INN | bradanicline |
| Description | Bradanicline (INN, code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.
|
| Classification | Small molecule |
| Drug class | nicotinic acetylcholine receptor partial agonists/agonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc2ccccc2o1 |
Identifiers
| PDB | — |
| CAS-ID | 639489-84-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1258006 |
| ChEBI ID | — |
| PubChem CID | 25147644 |
| DrugBank | DB06090 |
| UNII ID | UM3821998K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CHRNA7
CHRNA7
Organism
Homo sapiens
Gene name
CHRNA7
Gene synonyms
NACHRA7
NCBI Gene ID
Protein name
neuronal acetylcholine receptor subunit alpha-7
Protein synonyms
a7 nicotinic acetylcholine receptor, alpha 7 neuronal nicotinic acetylcholine receptor, alpha-7 nicotinic cholinergic receptor subunit, cholinergic receptor, nicotinic alpha 7, cholinergic receptor, nicotinic, alpha 7 (neuronal), cholinergic receptor, nicotinic, alpha polypeptide 7, neuronal acetylcholine receptor protein, alpha-7 chain
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more